Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...

Explore the breakthrough of lab-made lncRNA by University of Toronto Engineering for new drug discovery potential.

Discover why biomarkers are critical in modern drug discovery and clinical trials, enabling better target validation.

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...

A team led by Professor Inkyung Jung from the Department of Biological Sciences at KAIST, working with Professor Yarui Diao’s ...

Company’s exhibit theater presentation will highlight multiomic and multimodal innovations in rare disease diagnostics ...

Flowering time determines reproductive success in perennial trees, yet the epigenetic mechanisms underlying sexual asynchrony remain poorly understood.

MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in the life sciences, today announced the acquisition of STOmics and CycloneSEQ. It ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

In 2021, a technology developed at the University of Michigan, called Seq-Scope, revolutionized the ability to map gene ...

Announcing a new article publication for BIO Integration journal. Alzheimer's disease (AD) is a neurodegenerative disorder ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.